Discovery of inhibitors of aberrant gene transcription from libraries of DNA binding molecules: Inhibition of LEF-1-mediated gene transcription and oncogenic transformation

Journal of the American Chemical Society

Volumn 131, Issue 9, 2009, Pages 3342-3348

  Stover, James S ^a   Shi, Jin ^a   Jin, Wei ^a   Vogt, Peter K ^a   Boger, Dale L ^a  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ASSAYS; BINDING ENERGY; COMPLEXATION; DNA; GENES; LEAD COMPOUNDS; MOLECULES; TISSUE CULTURE; TRANSCRIPTION FACTORS;

CELL TRANSFORMATION; CELLULAR CHANGES; COMPOUND LIBRARIES; CONSENSUS SEQUENCE; DNA BINDING; DNA BINDING AFFINITY; DNA-BINDING PROPERTIES; FUNCTIONAL ACTIVITIES; FUNCTIONAL ASSAYS; GENE TRANSCRIPTIONS; INITIAL ASSESSMENT; INTERCALATORS; ONCOGENIC TRANSFORMATION; SELECTIVE BINDING; SMALL MOLECULE INHIBITOR; SYNTHETIC DNA;

TRANSCRIPTION;

ANTINEOPLASTIC AGENT; LEFMYCIN 1; LEFMYCIN 2; LYMPHOID ENHANCER FACTOR 1; UNCLASSIFIED DRUG; DNA; MOLECULAR LIBRARY;

ARTICLE; BINDING AFFINITY; DNA LIBRARY; DRUG SCREENING; DRUG SELECTIVITY; FLUORESCENCE ANALYSIS; FLUORESCENT INTERCALATOR DISPLACEMENT ASSAY; HUMAN; HUMAN CELL; MALIGNANT TRANSFORMATION; PHENOTYPE; PROTEIN DNA BINDING; TRANSCRIPTION TERMINATION; ANIMAL; ANTAGONISTS AND INHIBITORS; CELL LINE; CELL TRANSFORMATION; CHEMICAL STRUCTURE; CHEMISTRY; CHICKEN; COLON TUMOR; DOSE RESPONSE; DRUG DEVELOPMENT; DRUG EFFECTS; GEL MOBILITY SHIFT ASSAY; GENETIC TRANSCRIPTION; GENETICS; HIGH THROUGHPUT SCREENING; METABOLISM; MOLECULAR LIBRARY;

ANIMALS; CELL LINE; CELL TRANSFORMATION, NEOPLASTIC; CHICKENS; COLONIC NEOPLASMS; DNA; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG DISCOVERY; DRUG SCREENING ASSAYS, ANTITUMOR; ELECTROPHORETIC MOBILITY SHIFT ASSAY; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; LYMPHOID ENHANCER-BINDING FACTOR 1; MOLECULAR STRUCTURE; SMALL MOLECULE LIBRARIES; TRANSCRIPTION, GENETIC;

EID: 71749120003     PISSN: 00027863     EISSN: 15205126     Source Type: Journal    
DOI: 10.1021/ja809083d     Document Type: Article

References (48)

1. Tse, W. C; Boger, D. L. Chem. Biol. 2004, 11, 1607-1617.
2. Nickols, N. G.; Jacobs, C. S.; Farkas, M. E.; Dervan, P. B. Chem Biol. 2007, 2, 561-571.
3. Dervan, P. B.; Edelson, B. S. Curr. Opin. Struct. Biol. 2003, 13, 284-299.
4. Tse, W. C; Boger, D. L. Acc. Chem. Res. 2004, 37, 61-69.
5. (a) Boger, D. L.; Fink, B. E.; Brunette, S. R.; Tse, W. C; Hedrick, M. P. J. Am. Chem. Soc. 2001, 123, 5878-5891.
6. (b) Boger, D. L.; Tse, W. Bioorg. Med. Chem. 2001, 9, 2511-2518.
7. Boger, D. L.; Fink, B. E.; Hedrick, M. P. J, Am, Chem, Soc. 2000, 122, 6382-6394.
8. Approximately 50% of the Western population develop colorectal adenomas by the age of 70 (a) Ransohoff, D.; Lang, C. N. Engl. J. Med. 1991, 325, 37-41.
9. (b) At least 85% of these tumors contain APC mutations, see Powell, S. M.; Zilz, N.; Beazer-Barclay, Y.; Bryan, T. M.; Hamilton, S. R.; Thibodeau, S. N.; Vogelstein, B.; Kinzler, K. W. Nature 1992, 359, 235-237.
10. (c) Miyoshi, Y.; Nagase, H.; Ando, H.; Horii, A.; Ichii, S.; Nakatsuru, S.; Aoki, T.; Miki, Y.; Mori, T.; Nakamura, Y. Hum. Mol. Genet. 1992, 1, 229-233.
11. (d) Jen, J.; Powell, S. M.; Papadopoulos, N.; Smith, K. J.; Hamilton, S. R.; Vogelstein, B.; Kinzler, K. W. Cancer Res. 1994, 54, 5523-5526.
12. Novak, A.; Dedhar, S. Cell. Mol. Life. Scc. 1999, 56, 523-537.
13. Behrens, J. Cancer Metastasis Rev. 1999, 18, 15-30.
14. Eastman, Q.; Grosschedl, R. Cunm. Qpin. Cell Biol. 1999, 11, 233-240.
15. Morin, P. J.; Sparks, A. B.; Korinek, V.; Barker, N.; Clevers, H.; Vogelstein, B.; Kinzler, K. W. Science 1997, 275, 1787-1790.
16. Rubinfeld, B.; Robbins, P.; El-Gamil, M.; Albert, I.; Porfiri, E.; Polakis, P. Science 1997, 275, 1790-1792.
17. Munemitsu, S.; Albert, I.; Rubinfeld, B.; Polakis, P. Mol. Cell. Biol. 1996, 16, 4088-4094.
18. Carlsson, P.; Waterman, M. L.; Jones, K. A. Genes Dev. 1994, 7, 2418-2430.
19. Giese, K.; Grosschedl, R. EMBOJ. 1993, 12, 4667-4676.
20. Aoki, M.; Hecht, A.; Kruse, U.; Kemler, R.; Vogt, P. K. Proc. Natl. Acad. Sci. U. S. A. 1999, 96, 139-144.
21. Vogt, P. K.; Aoki, M.; Bottoli, I.; Chang, H. W.; Fu, S. L.; Hecht, A.; Iacovoni, J. S.; Jiang, B. H.; Kruse, U. Cell Growth Diff. 1999, 10, 777-784.
22. Aoki, M.; Sobek, V.; Maslyar, D. J.; Hecht, A.; Vogt, P. K. Oncogene 2002, 21, 6983-6991.
23. Korinek, V.; Barker, N.; Morin, P. J.; van Wichen, D.; de Weger, R.; Kinzler, K.; Vogelstein, B.; Clevers, H. Science 1997, 275, 1784-1787.
24. Travis, A.; Amsterdam, A.; Belanger, C.; Grosschedl, R. Genes Dev. 1991, 5, 880-894.
25. Waterman, M. L.; Jones, K. A. New Biol. 1990, 2, 621-636.
26. Waterman, M. L.; Fischer, W. H.; Jones, K. A. GenesDev. 1991, 5, 656-669.
27. van de Wetering, M.; Oosterwegel, M.; Dooijes, D.; Clevers, H. EMBO J. 1991, 10, 123-132.
28. Grosschedl, R.; Giese, K.; Pagel, J. Trends Genet. 1994, 10, 94-100.
29. Giese, K.; Amsterdam, A.; Grosschedl, R. Genes. Dev. 1991, 5, 2567-2578.
30. Ham, Y. W.; Tse, W. C.; Boger, D. L. Bioorg. Med. Chem. Lett. 2003, 13, 3805-3807.
31. Love, J. J.; Li, X.; Case, D.; Giese, K.; Grosschedl, R.; Wright, P. E. Nature 1995, 376, 791-795.
32. Dickinson, L. A.; Gulizia, R. J.; Trauger, J. W.; Baird, E. E.; Mosier, D. E.; Gottesfeld, J. M.; Dervan, P. B. Proc. Natl. Acad. Sci. U. S. A. 1998, 95, 12890-12895.
33. Cheng, S.; Comer, D. D.; Williams, J. P.; Boger, D. L. J. Am. Chem. Soc. 1996, 118, 2567-2573.
34. Cheng, S.; Tarby, C. M.; Comer, D. D.; Williams, J. P.; Caporale, L. H.; Boger, D. L. Bioorg. Med. Chem. 1996, 4, 727-737.
35. Boger, D. L.; Desharnais, J.; Capps, K. Angew. Chem., Int. Ed. 2003, 42, 4138-4176.
36. Dervan, P. B.; Doss, R. M.; Marques, M. A. Curr. Med. Chem.: Anti-Cancer Agents 2005, 5, 373-387.
37. Dervan, P. B.; Edelson, B. S. Curr. Opin. Struct. Biol. 2003, 13, 284-299.
38. Dervan, P. B. Bioorg. Med. Chem. 2001, 9, 2215-2235.
39. Dervan, P. B.; Bürli, R. W. Curr. Opin. Chem. Biol. 1999, 3, 688-693.
40. Boger, D. L.; Johnson, D. S. Angew. Chem., Int. Ed. Engl. 1996, 35, 1438-1474.
41. (a) Boger, D. L.; Garbaccio, R. M. Acc. Chem. Res. 1999, 32, 1043-1052.
42. (b) Tichenor, M. S.; Boger, D. L. Nat. Prod. Rep. 2008, 25, 220-226.
43. It is possible that a single uniquely active compound in a mixture may be missed by screening even such small mixtures (10 or 15 compounds). However, because two of the subunits of each compound in a given mixture are the same (same B and C subunits), it is more likely that each compound in a mixture exhibits a progressive range of related binding affinities and selectivities rather than exhibiting a unique behavior. As such, the screening of mixtures containing such common elements not only minimize the chances of missing a uniquely active compound, but it can often provide a first level SAR that distinguishes it from randomly combined 10-15 compound mixtures that are commonly used to expedite HTS. For our purposes and as shown herein, the approach provided useful lead structures utilizing equipment, reagent amounts, and time accessible in any academic laboratory. For more detailed documentation of testing such mixtures, see. (a) Ambroise, Y.; Yuspan, B.; Ginsberg, M. H.; Boger, D. L. Chem. Biol. 2002, 9, 1219-1226.
44. (b) Boger, D. L.; Dechantsreiter, M. A.; Ishii, T.; Fink, B. E.; Hedrick, M. P. Bioorg. Med. Chem. 2000, 8, 2049-2057.
45. (c) Boger, D. L.; Lee, J. K.; Goldberg, J.; Jin, Q. J. Org. Chem. 2000, 65, 1467-1474.
46. This library is available upon request for screening.
47. Bister, K.; Hayman, M. J.; Vogt, P. K. Virology 1977, 82, 431-448.
48. Tse, W.; Ishii, T.; Boger, D. L. Bioorg. Med. Chem. 2003, 11, 4479-4486.